How to best manage glycemia and non-glycemia during the time of acute myocardial infarction

Diabetes Technology and Therapeutics

Volumn 14, Issue SUPPL. 1, 2012, Pages

  Hirsch, Irl B ^a   O'Brien, Kevin D ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; FIBRINOLYTIC AGENT; GLUCOSE; GLUCOSE PLUS INSULIN PLUS POTASSIUM; HEMOGLOBIN A1C; HYPERGLYCEMIC AGENT; INSULIN; MORPHINE; OXYGEN; PRASUGREL; TICAGRELOR; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ANGINA PECTORIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLEEDING; BLOOD CLOT LYSIS; BLOOD GLUCOSE MONITORING; CARDIOGENIC SHOCK; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS SURGERY; CRITICALLY ILL PATIENT; DIABETES MELLITUS; DIET RESTRICTION; DISEASE ASSOCIATION; DRUG EFFICACY; GLYCEMIC CONTROL; HEART ARRHYTHMIA; HEART LEFT VENTRICLE FAILURE; HEART REINFARCTION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; MORBIDITY; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS;

ACUTE DISEASE; ANTICOAGULANTS; BLOOD GLUCOSE; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; INSULIN INFUSION SYSTEMS; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; PRACTICE GUIDELINES AS TOPIC; THROMBOLYTIC THERAPY; TIME FACTORS;

EID: 84861843744     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2012.0095     Document Type: Article

References (73)

1. Centers for Disease Control and Prevention: Giabetes Public Health Resource. www.cdc.gov/diabetes/pubs/estimates07. htm (accessed March 11, 2012).
2. Kannel WB, McGee DL: Giabetes and cardiovascular disease. The Framingham Study. JAMA 1979;241:2035-2038.
3. Ouhoummane N, Abdous B, Louchini R, Rochette L, Poirier P: Trends in postacute myocardial infarction management and mortality in patients with diabetes. A population-based study from 1995 to 2001. Can J Cardiol 2010;26:523-531.
4. Capes SE, Hunt D, Malmberg K, Gerstein HC: Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: A systematic overview. Lancet 2000;355:773-778.
5. Ishihara M, Kojima S, Sakamoto T, Asada Y, Tei C, Kimura K, Miyazaki S, Sonoda M, Tsuchihashi K, Yamagishi M, Ikeda Y, Shirai M, Hiraoka H, Inoue T, Saito F, Ogawa H; Japanese Acute Coronary Syndrome Study Investigators: Acute hyperglycemia is associated with adverse outcome after acute myocardial infarction in the coronary intervention era. Am Heart J 2005;150:814-820.
6. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, Quagliaro L, Ceriello A, Giugliano D: Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: Role of oxidative stress. Circulation 2002;106:2067-2072.
7. Giacco F, Brownlee M: Oxidative stress and diabetic complications. Circ Res 2010;107:1058-1070.
8. Risso A, Mercuri F, Quagliaro L, Damante G, Ceriello A: Intermittent high glucose enhances apoptosis in human umbilical vein endothelial cells in culture. Am J Physiol Endocrinol Metab 2001;281:E924-E930.
9. Calles-Escandon J, Cipolla M: Giabetes and endothelial dysfunction: A clinical perspective. Endocr Rev 2001;22:36-52.
10. Carr ME: Giabetes mellitus: A hypercoagulable state. J Diabetes Complications 2001;15:44-54.
11. Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL: Platelet dysfunction in type 2 diabetes. Diabetes Care 2001;24:1476-1485.
12. Eisen A, Fisman EZ, Rubenfire M, Freimark D, McKechnie R, Tenenbaum A, Motro M, Adler Y: Ischemic preconditioning: Nearly two decades of research. A comprehensive review. Atherosclerosis 2004;172:201-210.
13. Meinert CL, Knatterud GL, Prout TE, Klimt CR: A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970;19(Suppl):789-830.
14. Meier JJ, Gallwitz B, Schmidt WE, Mü gge A, Nauck MA: Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important? Heart 2004;90:9-12.
15. Razavi Nematollahi L, Kitabchi AE, Stentz FB, Wan JY, Larijani BA, Tehrani MM, Gozashti MH, Omidfar K, Taheri E: Proinflammatory cytokines in response to insulin-induced hypoglycemic stress in healthy subjects. Metabolism 2009; 58:443-448.
16. NICE-SUGAR Study Investigators, Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, Bellomo R, Cook D, Dodek P, Henderson WR, Hébert PC, Heritier S, Heyland DK, McArthur C, McDonald E, Mitchell I, Myburgh JA, Norton R, Potter J, Robinson BG, Ronco JJ: Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009;360:1283-1297.
17. Rana O, Byrne CD, Kerr D, Coppini DV, Zouwail S, Senior R, Begley J, Walker JJ, Greaves K: Acute hypoglycemia decreases myocardial blood flow reserve in patients with type 1 diabetes mellitus and in healthy humans. Circulation 2011;124:1548-1556.
18. Nordin C: The case for hypoglycaemia as a proarrhythmic event: Basic and clinical evidence. Diabetologia 2010;53: 1552-1561.
19. Kosuge M, Kimura K, Ishikawa T, Shimizi T, Hibi K, Toda N, Tahara Y, Kanna M, Tsukahara K, Okuda J, Nozawa N, Umemura S: Persistent hyperglycemia is associated with left ventricular dysfunction in patients with acute myocardial infarction. Circ J 2005;69:23-28.
20. Goyal A, Mahaffey KW, Garg J, Nicolau JC, Hochman JS, Weaver WD, Theroux P, Oliveira GB, Todaro TG, Mojcik CF, Armstrong PW, Granger CB: Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: Results from the CARDINAL study. Eur Heart J 2006;27:1289-1297.
21. Pittas AG, Siegel RD, Lau J: Insulin therapy for critically ill hospitalized patients: A meta-analysis of randomized controlled trials. Arch Intern Med 2004;164:2005-2011.
22. Sodi-Pallares D, Testelli MR, Fishleder BL, Bisteni A, Medrano GA, Friedland C, De Micheli A: Effects of an intravenous infusion of a potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction. A preliminary clinical report. Am J Cardiol 1962;9:166-181.
23. Opie LH: Myocardial infarct size. Part 2. Comparison of anti-infarct effects of beta-blockade, glucose-insulin-potassium, nitrates, and hyaluronidase. Am Heart J 1980;100: 531-552.
24. Díaz R, Paolasso EA, Piegas LS, Tajer CD, Moreno MG, Corvalán R, Isea JE, Romero G: Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardioló -gicos Latinoamérica) Collaborative Group. Circulation 1998;98:2227-2234.
25. Mehta SR, Yusuf S, Díaz R, Zhu J, Pais P, Xavier D, Paolasso E, Ahmed R, Xie C, Kazmi K, Tai J, Orlandini A, Pogue J, Liu L; CREATE-ECLA Trial Group Investigators: Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: The CREATE-ECLA randomized controlled trial. JAMA 2005;293:437-446.
26. Malmberg K, Rydén L, Efendic S, Herlitz J, Nicol P, Waldenström A, Wedel H, Welin L: Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): Effects on mortality at 1 year. J Am Coll Cardiol 1995;26:57-65.
27. Malmberg K, Rydén L, Wedel H, Birkeland K, Bootsma A, Dickstein K, Efendic S, Fisher M, Hamsten A, Herlitz J, Hildebrandt P, MacLeod K, Laakso M, Torp-Pedersen C, Waldenström A; DIGAMI 2 Investigators: Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): Effects on mortality and morbidity. Eur Heart J 2005;26:650-661.
28. Selker HP, Beshansky JR, Sheehan PR, Massaro JM, Griffith JL, D'Agostino RB, Ruthazer R, Atkins JM, Sayah AJ, Levy MK, Richards ME, Aufderheide TP, Braude DA, Pirrallo RG, Doyle DD, Frascone RJ, Kosiak DJ, Leaming JM, Van Gelder CM, Walter GP, Wayne MA, Woolard RH, Opie LH, Rackley CE, Apstein CS, Udelson JE: Out-of-hospital administration of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes: The IMMEDIATE randomized controlled trial. JAMA 2012 Mar 27 [Epub ahead of print]. DOI: 10.1001/jama.2012.426.
29. Marik PE, Preiser JC: Toward understanding tight glycemic control in the ICU: A systematic review and metaanalysis. Chest 2010;137:544-551.
30. Wright RJ, Newby DE, Stirling D, Ludlam CA, Macdonald IA, Frier BM: Effects of acute insulin-induced hypoglycemia on indices of inflammation: Putative mechanism for aggravating vascular disease in diabetes. Diabetes Care 2010;33:1591-1597.
31. Desouza C, Salazar H, Cheong B, Murgo J, Fonseca V: Association of hypoglycemia and cardiac ischemia: A study based on continuous monitoring. Diabetes Care 2003;26:1485-1489.
32. Landstedt-Hallin L, Englund A, Adamson U, Lins PE: Increased QT dispersion during hypoglycaemia in patients with type 2 diabetes mellitus. J Intern Med 1999;246:299-307.
33. Moghissi ES, Korytkowski MT, DiNardo M, Einhorn D, Hellman R, Hirsch IB, Inzucchi SE, Ismail-Beigi F, Kirkman MS, Umpierrez GE; American Association of Clinical Endocrinologists; American Diabetes Association: American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care 2009;32:1119-1131.
34. Ku SY, Sayre CA, Hirsch IB, Kelly JL: New insulin infusion protocol improves blood glucose control in hospitalized patients without increasing hypoglycemia. Jt Comm J Qual Patient Saf 2005;31:141-147.
35. Moreno PR, Murcia AM, Palacios IF, Leon MN, Bernardi VH, Fuster V, Fallon JT: Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation 2000;102:2180-2184.
36. Burke AP, Kolodgie FD, Zieske A, Fowler DR, Weber DK, Varghese PJ, Farb A, Virmani R: Morphologic findings of coronary atherosclerotic plaques in diabetics: A postmortem study. Arterioscler Thromb Vasc Biol 2004;24:1266-1271.
37. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J: Risk of thrombosis in human atherosclerotic plaques: Role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 1993;69:377-381.
38. Richardson PD, Davies MJ, Born GV: Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 1989;2:941-944.
39. Nikkari ST, O'Brien KD, Ferguson M, Hatsukami T, Welgus HG, Alpers CE, Clowes AW: Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. Circulation 1995;92:1393-1398.
40. Galis ZS, Sukhova GK, Kranzhö fer R, Clark S, Libby P: Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Natl Acad Sci U S A 1995;92:402-406.
41. Mizushige K, Noma T, Yao L, Yu Y, Kiyomoto H, Hosomi N, Fukui T, Kimura S, Abe Y, Matsuo H: Effects of troglitazone on collagen accumulation and distensibility of aortic wall in prestage of non-insulin-dependent diabetes mellitus of Otsuka Long-Evans Tokushima Fatty rats. J Cardiovasc Pharmacol 2000;35:150-155.
42. Candido R, Allen TJ, Lassila M, Cao Z, Thallas V, Cooper ME, Jandeleit-Dahm KA: Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis. Circulation 2004;109:1536-1542.
43. McDonald TO, Gerrity RG, Jen C, Chen HJ, Wark K, Wight TN, Chait A, O'Brien KD: Giabetes and arterial extracellular matrix changes in a porcine model of atherosclerosis. J Histochem Cytochem 2007;55:1149-1157.
44. Sobel BE, Woodcock-Mitchell J, Schneider DJ, Holt RE, Marutsuka K, Gold H: Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: A potential factor predisposing to thrombosis and its persistence. Circulation 1998;97:2213-2221.
45. Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH: Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: Progressive, interrelated, and independently associated with risk of death. Diabetes 2002;51: 1157-1165.
46. Woodfield SL, Lundergan CF, Reiner JS, Greenhouse SW, Thompson MA, Rohrbeck SC, Deychak Y, Simoons ML, Califf RM, Topol EJ, Ross AM: Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: The GUSTO-I experience. J Am Coll Cardiol 1996;28:1661-1669.
47. Chin CT, Chen AY, Wang TY, Alexander KP, Mathews R, Rumsfeld JS, Cannon CP, Fonarow GC, Peterson ED, Roe MT: Risk adjustment for in-hospital mortality of contemporary patients with acute myocardial infarction: The Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry-Get with the Guidelines (GWTG) acute myocardial infarction mortality model and risk score. Am Heart J 2011;161:113-122.
48. Murcia AM, Hennekens CH, Lamas GA, Jiménez-Navarro M, Rouleau JL, Flaker GC, Goldman S, Skali H, Braunwald E, Pfeffer MA: Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction. Arch Intern Med 2004;164:2273-2279.
49. Aguilar D, Solomon SD, Køber L, Rouleau JL, Skali H, McMurray JJ, Francis GS, Henis M, O'Connor CM, Diaz R, Belenkov YN, Varshavsky S, Leimberger JD, Velazquez EJ, Califf RM, Pfeffer MA: Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: The VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Circulation 2004;110:1572-1578.
50. Bauer T, Möllmann H, Weidinger F, Zeymer U, Seabra-Gomes R, Eberli F, Serruys P, Vahanian A, Silber S, Wijns W, Hochadel M, Nef HM, Hamm CW, Marco J, Gitt AK: Impact of diabetes mellitus status on coronary pathoanatomy and interventional treatment: Insights from the Euro Heart Survey PCI registry. Catheter Cardiovasc Interv 2011;78: 702-709.
51. Held C, Gerstein HC, Yusuf S, Zhao F, Hilbrich L, Anderson C, Sleight P, Teo K; ONTARGET/TRANSCEND Investigators: Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. Circulation 2007;115:1371-1375.
52. Bertoni AG, Tsai A, Kasper EK, Brancati FL: Giabetes and idiopathic cardiomyopathy: A nationwide case-control study. Diabetes Care 2003;26:2791-2795.
53. Poirier P, Bogaty P, Garneau C, Marois L, Dumesnil JG: Giastolic dysfunction in normotensive men with well-controlled type 2 diabetes: Importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care 2001;24:5-10.
54. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ: Burden of systolic and diastolic ventricular dysfunction in the community: Appreciating the scope of the heart failure epidemic. JAMA 2003;289:194-202.
55. Liu JE, Robbins DC, Palmieri V, Bella JN, Roman MJ, Fabsitz R, Howard BV, Welty TK, Lee ET, Devereux RB: Association of albuminuria with systolic and diastolic left ventricular dysfunction in type 2 diabetes: The Strong Heart Study. J Am Coll Cardiol 2003;41:2022-2028.
56. Factor SM, Minase T, Sonnenblick EH: Clinical and morphological features of human hypertensive-diabetic cardiomyopathy. Am Heart J 1980;99:446-458.
57. Boudina S, Abel ED: Giabetic cardiomyopathy revisited. Circulation 2007;115:3213-3223.
58. Ravingerova T, Neckar J, Kolar F, Stetka R, Volkovova K, Ziegelhö ffer A, Styk J.: Ventricular arrhythmias following coronary artery occlusion in rats: Is the diabetic heart less or more sensitive to ischaemia? Basic Res Cardiol 2001;96:160-168.
59. Mehta RH, Yu J, Piccini JP, Tcheng JE, Farkouh ME, Reiffel J, Fahy M, Mehran R, Stone GW: Prognostic significance of postprocedural sustained ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention (from the HORIZONS-AMI Trial). Am J Cardiol 2012;109:805-812.
60. Sanjuan R, Blasco ML, Martinez-Maicas H, Carbonell N, Miñana G, Nuñez J, Bodí V, Sanchis J: Acute myocardial infarction: High risk ventricular tachyarrhythmias and admission glucose level in patients with and without diabetes mellitus. Curr Diabetes Rev 2011;7:126-134.
61. Gill GV, Woodward A, Casson IF, Weston PJ: Cardiac arrhythmia and nocturnal hypoglycaemia in type 1 diabetes-The 'dead in bed' syndrome revisited. Diabetologia 2009;52:42-45.
62. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr, Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Canadian Cardiovascular Society: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 2004;110:e82-e292. Erratum in Circulation 2005;111:2013-2014, Circulation 2007;115:e411, Circulation 2010;121:e441.
63. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr, Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Canadian Cardiovascular Society: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 2004;110:e82-e292. Erratum in Circulation 2005;111:2013-2014, Circulation 2007;115:e411, Circulation 2010;121:e441.
64. Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM, Bailey SR, Bates ER, Blankenship JC, Casey De Jr, Green LA, Hochman JS, Jacobs AK, Krumholz HM, Morrison DA, Ornato JP, Pearle DL, Peterson ED, Sloan MA, Whitlow PL, Williams DO; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009; 120:2271-2306. Erratum in Circulation 2010;121:e257. Dosage error in article text.
65. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey De Jr, Chavey WE 2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC Jr, Jacobs AK, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B; American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non STElevation Myocardial Infarction); American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association of Cardiovascular and Pulmonary Rehabilitation; Society for Academic Emergency Medicine: ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to evise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non STElevation Myocardial Infarction): Geveloped in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007;116:e148-e304. Erratum in Circulation 2008;117:e180.
66. Keeley EC, Boura JA, Grines CL: Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review of 23 randomised trials. Lancet 2003;361:13-20.
67. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. N Engl J Med 1996;335:217-225. Erratum in N Engl J Med 1997;336:147.
68. Schwartz L, Bertolet M, Feit F, Fuentes F, Sako EY, Toosi MS, Davidson CJ, Ikeno F, King SB 3rd: Impact of completeness of revascularization on long-Term cardiovascular outcomes in patients with type 2 diabetes mellitus: Results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D). Circ Cardiovasc Interv 2012 Apr 10 [Epub ahead of print]. DOI: 10.1161/CIRCINTERVENTIONS .111.963512.
69. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994;308:81-106. Erratum in BMJ 1994;308:1540.
70. Nijjer SS, Davies JE, Francis DP: Quantitative comparison of clopidogrel 600mg, prasugrel and ticagrelor, against clopidogrel 300mg on major adverse cardiovascular events and bleeding in coronary stenting: Synthesis of CURRENTOASIS-7, TRITON-TIMI-38 and PLATO. Int J Cardiol 2012 Jan 10 [Epub ahead of print]. DOI: 10.1016/j.ijcard.2011.12.046.
71. Yudkin JS: Managing the diabetic patient with acute myocardial infarction. Diabet Med 1998;15:276-281.
72. Gottlieb SS, McCarter RJ, Vogel RA: Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998;339:489-497.
73. Hirsch IB, Boyle PJ, Craft S, Cryer PE: Higher glycemic thresholds for symptoms during beta-adrenergic blockade in IDDM. Diabetes 1991;40:1177-1186.